Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Intralesional injection of antimony has been used for L major from Iran with a modest cure
rate [56%: Asilian 2004]. However, this therapeutic approach has been used for L braziliensis
from Brazil, with an attractive cure rate after 3 months of 80% [Oliveira-Neto 1997]. Because
intralesional Sb injections is the local therapy with the best reported cure rate for South
American L braziliensis disease, the species that causes disease in Bolivia, this pilot study
of local therapy for bolivian L braziliensis disease will evaluate intralesional Sb therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Fundacion Nacional de Dermatologia
Collaborators:
Hospital Dermatológico de Jorochito Proyecto OSCAR The Alfred Berman Foundation for Medical Research Universidad Mayor de San Simón